Cargando…
Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression
BACKGROUND: Glutathione S-transferase mu 3 (GSTM3) has been proven to be downregulated in renal cell carcinoma (RCC). We aimed to characterise the role of GSTM3 and its genetic predisposition on the occurrence and postoperative prognosis of RCC. METHODS: The effect of GSTM3 on RCC aggressiveness was...
Autores principales: | Tan, X, Wang, Y, Han, Y, Chang, W, Su, T, Hou, J, Xu, D, Yu, Y, Ma, W, Thompson, T C, Cao, G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859948/ https://www.ncbi.nlm.nih.gov/pubmed/24157827 http://dx.doi.org/10.1038/bjc.2013.669 |
Ejemplares similares
-
Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis
por: Hsiao, J-R, et al.
Publicado: (2003) -
Distinct association between aberrant methylation of Wnt inhibitors and genetic alterations in acute myeloid leukaemia
por: Hou, H-A, et al.
Publicado: (2011) -
COX2 genetic variation, NSAIDs, and advanced prostate cancer risk
por: Cheng, I, et al.
Publicado: (2007) -
Frequent reduced expression of alpha-1B-adrenergic receptor caused by aberrant promoter methylation in gastric cancers
por: Noda, H, et al.
Publicado: (2007) -
Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells
por: Hong, D, et al.
Publicado: (2009)